Hindsight is 20/20 and predicting clinical trial results is rarely easy, but the falls of OXiGENE
OXiGENE said yesterday that combining its oncology drug Zybrestat with Roche's Avastin and two chemotherapy drugs didn't extend survival of lung cancer patients beyond what Avastin plus standard chemotherapy could do on their own.
Rexahan's decline stems from a failed clinical trial as well. One of the company's lead compounds, Serdaxin, failed to decrease symptoms of depression more than placebo.
What telltale sign should have helped investors realize that the companies were a long shot? Before the news, Rexahan was a $97 million company and OXiGENE only sported a market cap of a measly $27 million. The discount price means potentially higher returns, but that could also be a sign there's something amiss.
You have to assume that many investors -- probably with substantially larger portfolios than yours -- have already looked at the relatively cheap biotech and passed. The market will miss a few, but in general they tend to do a good job knocking down the value of long-shot biotechs.
I think most investors would be best off avoiding all biotechs with sub-$100 million market caps. Sure, you'll miss some rockets. Vanda Pharmaceuticals
While I'd argue for giving up the dark horses that have the potential to bring mind-blowing gains, there's still plenty to be made in biotechs that have been vetted and assigned higher values by investors. Inhibitex
The Fool's Rule Breakers newsletter service searches for new technologies that can produce outsized gains. Watch this video about why they think near field communication is set to break the rules and how to profit from it.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.